1. Dalstein V, Riethmuller D, Pretet JL, Le Bail Carval K, Sautiere JL, Carbillet JP, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer 2003;106:396-403. PMID:
12845680.
2. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 2001;286:3106-3114. PMID:
11754676.
3. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 1992;79:328-337. PMID:
1310805.
4. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19. PMID:
10451482.
5. Heard I, Tassie JM, Schmitz V, Mandelbrot L, Kazatchkine MD, Orth G. Increased risk of cervical disease among human immunodeficiency virus-infected women with severe immunosuppression and high human papillomavirus load. Obstet Gynecol 2000;96:403-409. PMID:
10960634.
6. Lai HC, Peng MY, Nieh S, Yu CP, Chang CC, Lin YW, et al. Differential viral loads of human papillomavirus 16 and 58 infections in the spectrum of cervical carcinogenesis. Int J Gynecol Cancer 2006;16:730-735. PMID:
16681753.
7. Roberts I, Ng G, Foster N, Stanley M, Herdman MT, Pett MR, et al. Critical evaluation of HPV16 gene copy number quantification by SYBR green PCR. BMC Biotechnol 2008;8:57PMID:
18652663.
8. Ramanakumar AV, Goncalves O, Richardson H, Tellier P, Ferenczy A, Coutlee F, et al. Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women. BMC Infect Dis 2010;10:326PMID:
21070660.
9. Arias-Pulido H, Peyton CL, Joste NE, Vargas H, Wheeler CM. Human papillomavirus type 16 integration in cervical carcinoma in situ and in invasive cervical cancer. J Clin Microbiol 2006;44:1755-1762. PMID:
16672403.
10. Vaccarella S, Franceschi S, Snijders PJ, Herrero R, Meijer CJ, Plummer M, et al. Concurrent infection with multiple human papillomavirus types: pooled analysis of the IARC HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 2010;19:503-510. PMID:
20142247.
11. Schmitt M, Depuydt C, Benoy I, Bogers J, Antoine J, Arbyn M, et al. Multiple human papillomavirus infections with high viral loads are associated with cervical lesions but do not differentiate grades of cervical abnormalities. J Clin Microbiol 2013;51:1458-1464. PMID:
23447632.
12. De-Castro Arce J, Gockel-Krzikalla E, Rosl F. Retinoic acid receptor beta silences human papillomavirus-18 oncogene expression by induction of de novo methylation and heterochromatinization of the viral control region. J Biol Chem 2007;282:28520-28529. PMID:
17686773.
13. Carbone M, Klein G, Gruber J, Wong M. Modern criteria to establish human cancer etiology. Cancer Res 2004;64:5518-5524. PMID:
15289363.
14. Santos AL, Derchain SF, Martins MR, Sarian LO, Martinez EZ, Syrjanen KJ. Human papillomavirus viral load in predicting high-grade CIN in women with cervical smears showing only atypical squamous cells or low-grade squamous intraepithelial lesion. Sao Paulo Med J 2003;121:238-243. PMID:
14989139.
15. Broccolo F, Chiari S, Piana A, Castiglia P, Dell’Anna T, Garcia-Parra R, et al. Prevalence and viral load of oncogenic human papillomavirus types associated with cervical carcinoma in a population of North Italy. J Med Virol 2009;81:278-287. PMID:
19107971.
16. Murall CL, Bauch CT, Day T. Could the human papillomavirus vaccines drive virulence evolution? Proc Biol Sci 2015;282:20141069PMID:
25429011.
17. Elfstrom KM, Dillner J, Arnheim-Dahlstrom L. Organization and quality of HPV vaccination programs in Europe. Vaccine 2015;33:1673-1681. PMID:
25720792.
18. Kumar RV, Bhasker S. Potential opportunities to reduce cervical cancer by addressing risk factors other than HPV. J Gynecol Oncol 2013;24:295-297. PMID:
24167663.
19. Kim TJ, Jin HT, Hur SY, Yang HG, Seo YB, Hong SR, et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients. Nat Commun 2014;5:5317PMID:
25354725.
20. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York (NY): John Wiley and Sons; 1981.
21. Cai YP, Yang Y, Zhu BL, Li Y, Xia XY, Zhang RF, et al. Comparison of human papillomavirus detection and genotyping with four different prime sets by PCR-sequencing. Biomed Environ Sci 2013;26:40-47. PMID:
23294614.
22. Husnjak K, Grce M, Magdic L, Pavelic K. Comparison of five different polymerase chain reaction methods for detection of human papillomavirus in cervical cell specimens. J Virol Methods 2000;88:125-134. PMID:
10960700.
23. Bae JH, Lee SJ, Kim CJ, Hur SY, Park YG, Lee WC, et al. Human papillomavirus (HPV) type distribution in Korean women: a meta-analysis. J Microbiol Biotechnol 2008;18:788-794. PMID:
18467878.
24. Hariri S, Unger ER, Sternberg M, Dunne EF, Swan D, Patel S, et al. Prevalence of genital human papillomavirus among females in the United States, the National Health And Nutrition Examination Survey, 2003-2006. J Infect Dis 2011;204:566-573. PMID:
21791659.
25. Hwang HS, Park M, Lee SY, Kwon KH, Pang MG. Distribution and prevalence of human papillomavirus genotypes in routine pap smear of 2,470 korean women determined by DNA chip. Cancer Epidemiol Biomarkers Prev 2004;13:2153-2156. PMID:
15598774.
26. An HJ, Cho NH, Lee SY, Kim IH, Lee C, Kim SJ, et al. Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method. Cancer 2003;97:1672-1680. PMID:
12655524.